Shares of Moleculin Biotech sank another 9.1% to $0.26 on October 19, capping a brutal week that has erased more than 40% of the stock's value since October 12. The catalyst: a 1-for-20 reverse stock split disclosed on October 16, set to take effect October 20 . For a company worth roughly $5.7 million, the move is less about corporate strategy and more about survival on the Nasdaq.
• This Is the Company's Third Reverse Split Since 2024 — and the Math Keeps Getting Worse
Moleculin executed a 1-for-15 reverse split in March 2024 , then a 1-for-25 split in December 2025 . Now comes a 1-for-20. Each consolidation temporarily lifts the per-share price to satisfy Nasdaq's $1.00 minimum bid rule, but each time the stock slides back below that threshold. From July 31 through September 11, 2026, the stock traded below $1.00 for 30 consecutive days , triggering yet another delisting notice. Serial reverse splits are a hallmark of companies in a dilution death spiral — they shrink the share count to boost the price, but the underlying business hasn't changed.
• Nasdaq Has Already Warned There May Be No More Second Chances
Nasdaq told Moleculin it was not eligible for the standard 180-day compliance period because it had conducted a reverse split within the prior year . That forced the company to request a hearing to stay delisting. If this latest split fails to hold the price above $1.00, Moleculin may have no procedural lifeline left.
• The Cash Situation Leaves Almost No Margin for Error
BiopharmaWatch estimates the company's cash runway at roughly one month, with "high dilution risk."
Moleculin itself has warned it needs "significant additional financing" for which it has no commitments . Its lead drug candidate is in a mid-stage cancer trial, but trials cost money the company doesn't appear to have.
• No Institutional Interest Signals Deep Market Skepticism
The company generates zero revenue, making standard valuation metrics meaningless . There is no reported institutional or high-profile investor interest , and the total market cap sits at just $5.71 million . When tomorrow's post-split trading begins, 20 old shares become one — but the underlying value proposition remains unchanged. Investors should watch whether the stock holds above $1.00 in coming weeks; if it doesn't, delisting risk becomes existential.